MorphoSys AG (MPSYF)
USD 73.27
(0.0%)
USD 73.27
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 238.27 Million EUR | -14.37% |
| 2022 | 278.26 Million EUR | 54.94% |
| 2021 | 179.6 Million EUR | -45.19% |
| 2020 | 327.69 Million EUR | 356.69% |
| 2019 | 71.75 Million EUR | -6.13% |
| 2018 | 76.44 Million EUR | 14.45% |
| 2017 | 66.79 Million EUR | 34.27% |
| 2016 | 49.74 Million EUR | -53.17% |
| 2015 | 106.22 Million EUR | 66.03% |
| 2014 | 63.97 Million EUR | -17.93% |
| 2013 | 77.96 Million EUR | 50.16% |
| 2012 | 51.91 Million EUR | -48.48% |
| 2011 | 100.77 Million EUR | 15.79% |
| 2010 | 87.03 Million EUR | 7.42% |
| 2009 | 81.02 Million EUR | 13.09% |
| 2008 | 71.64 Million EUR | 15.63% |
| 2007 | 61.96 Million EUR | 16.84% |
| 2006 | 53.03 Million EUR | 564.66% |
| 2005 | 7.97 Million EUR | -63.7% |
| 2004 | 21.97 Million EUR | 43.57% |
| 2003 | 15.3 Million EUR | -8.64% |
| 2002 | 16.75 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 27.53 Million EUR | -53.38% |
| 2023 Q1 | 62.31 Million EUR | -23.69% |
| 2023 Q4 | 59.07 Million EUR | -7.4% |
| 2023 Q3 | 63.8 Million EUR | 20.0% |
| 2023 FY | 238.27 Million EUR | -14.37% |
| 2023 Q2 | 53.16 Million EUR | -14.69% |
| 2022 Q3 | 95.7 Million EUR | 61.0% |
| 2022 Q4 | 81.66 Million EUR | -14.66% |
| 2022 Q1 | 41.5 Million EUR | -21.55% |
| 2022 FY | 278.26 Million EUR | 54.94% |
| 2022 Q2 | 59.44 Million EUR | 43.23% |
| 2021 Q2 | 38.2 Million EUR | -19.05% |
| 2021 FY | 179.6 Million EUR | -45.19% |
| 2021 Q3 | 41.24 Million EUR | 7.97% |
| 2021 Q1 | 47.18 Million EUR | 30.92% |
| 2021 Q4 | 52.9 Million EUR | 28.26% |
| 2020 Q1 | 251.22 Million EUR | 2167.83% |
| 2020 Q4 | 36.04 Million EUR | 63.85% |
| 2020 Q3 | 21.99 Million EUR | 19.33% |
| 2020 FY | 327.69 Million EUR | 356.69% |
| 2020 Q2 | 18.43 Million EUR | -92.66% |
| 2019 Q4 | 11.07 Million EUR | -11.19% |
| 2019 Q1 | 13.54 Million EUR | 29.23% |
| 2019 Q2 | 34.65 Million EUR | 155.8% |
| 2019 FY | 71.75 Million EUR | -6.13% |
| 2019 Q3 | 12.47 Million EUR | -64.01% |
| 2018 Q1 | 2.79 Million EUR | -90.06% |
| 2018 Q4 | 10.48 Million EUR | -80.95% |
| 2018 Q2 | 8.12 Million EUR | 190.3% |
| 2018 FY | 76.44 Million EUR | 14.45% |
| 2018 Q3 | 55.03 Million EUR | 577.36% |
| 2017 Q1 | 11.84 Million EUR | -9.06% |
| 2017 FY | 66.79 Million EUR | 34.27% |
| 2017 Q4 | 28.15 Million EUR | 87.11% |
| 2017 Q3 | 15.04 Million EUR | 28.08% |
| 2017 Q2 | 11.74 Million EUR | -0.77% |
| 2016 Q2 | 12.16 Million EUR | 0.55% |
| 2016 FY | 49.74 Million EUR | -53.17% |
| 2016 Q4 | 13.02 Million EUR | 4.44% |
| 2016 Q3 | 12.46 Million EUR | 2.51% |
| 2016 Q1 | 12.09 Million EUR | -1.77% |
| 2015 Q4 | 12.31 Million EUR | 8.95% |
| 2015 FY | 106.22 Million EUR | 66.03% |
| 2015 Q3 | 11.3 Million EUR | -7.33% |
| 2015 Q2 | 12.19 Million EUR | -82.68% |
| 2015 Q1 | 70.41 Million EUR | 313.45% |
| 2014 Q1 | 15.87 Million EUR | 10.5% |
| 2014 FY | 63.97 Million EUR | -17.93% |
| 2014 Q4 | 17.03 Million EUR | 3.85% |
| 2014 Q3 | 16.39 Million EUR | 11.79% |
| 2014 Q2 | 14.67 Million EUR | -7.6% |
| 2013 Q4 | 14.36 Million EUR | -6.44% |
| 2013 Q2 | 31.31 Million EUR | 85.06% |
| 2013 FY | 77.96 Million EUR | 50.16% |
| 2013 Q1 | 16.91 Million EUR | 453.1% |
| 2013 Q3 | 15.35 Million EUR | -50.95% |
| 2012 Q1 | 16.13 Million EUR | -5.48% |
| 2012 Q2 | 16.86 Million EUR | 4.53% |
| 2012 Q3 | 15.86 Million EUR | -5.91% |
| 2012 Q4 | 3.05 Million EUR | -80.72% |
| 2012 FY | 51.91 Million EUR | -48.48% |
| 2011 Q1 | 48.58 Million EUR | 100.28% |
| 2011 FY | 100.77 Million EUR | 15.79% |
| 2011 Q2 | 18.02 Million EUR | -62.89% |
| 2011 Q4 | 17.06 Million EUR | -0.22% |
| 2011 Q3 | 17.1 Million EUR | -5.13% |
| 2010 Q4 | 24.25 Million EUR | 25.57% |
| 2010 FY | 87.03 Million EUR | 7.42% |
| 2010 Q1 | 20.56 Million EUR | -12.26% |
| 2010 Q2 | 22.89 Million EUR | 11.33% |
| 2010 Q3 | 19.31 Million EUR | -15.63% |
| 2009 Q3 | 19.7 Million EUR | 5.15% |
| 2009 Q4 | 23.43 Million EUR | 18.93% |
| 2009 FY | 81.02 Million EUR | 13.09% |
| 2009 Q2 | 18.74 Million EUR | -2.04% |
| 2009 Q1 | 19.13 Million EUR | 0.0% |
| 2008 FY | 71.64 Million EUR | 15.63% |
| 2007 FY | 61.96 Million EUR | 16.84% |
| 2006 FY | 53.03 Million EUR | 564.66% |
| 2005 FY | 7.97 Million EUR | -63.7% |
| 2004 FY | 21.97 Million EUR | 43.57% |
| 2003 FY | 15.3 Million EUR | -8.64% |
| 2002 FY | 16.75 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -1410.672% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -1352140.582% |
| SQZ Biotechnologies Company | 21.47 Million USD | -1009.406% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -1207.928% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -93.795% |
| Mesoblast Limited | 5.9 Million USD | -3937.247% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Genus plc | 668.8 Million USD | 64.372% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -57993.283% |
| Marizyme, Inc. | 645.81 Thousand USD | -36796.04% |
| ContraFect Corporation | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -310315.853% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -362421.776% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -602861.468% |
| MultiCell Technologies, Inc. | 49.32 USD | -483127055.312% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -379.231% |
| EV Biologics, Inc. | 48.9 Thousand USD | -487176.714% |
| Q BioMed Inc. | 284.35 Thousand USD | -83696.953% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -705.076% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 2.869% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -340297.59% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -240599.753% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -314566.834% |
| IMV Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -36085.013% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 98.378% |
| Halberd Corporation | 999.00 USD | -23851582.983% |
| Enzolytics Inc. | 52.79 Thousand USD | -451218.875% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -17305.282% |
| SYBLEU INC | 11.69 Thousand USD | -2037163.278% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -39056.701% |
| argenx SE | 1.22 Billion USD | 80.57% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -12233.246% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -38494.831% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 71.618% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -64.217% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -42624.411% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -23782.139% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -392.779% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -1328.064% |
| ONE Bio Corp. | 52.29 Million USD | -355.632% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -100626.375% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -100626.375% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -169805.102% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -50198.337% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -2959.164% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -1832810.1% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -602617.441% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -7055.505% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -3475.068% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -22833.428% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -824.742% |
| CSL Limited | 14.8 Billion USD | 98.39% |
| Cellectis S.A. | 755 Thousand USD | -31460.041% |